SXTC
China SXT Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$671K
5Y Perf.-100.0%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
SXTC vs CCRN vs AMN vs SBFM vs TBI
Revenue, margins, valuation, and 5-year total return — side by side.
CCRN
Cross Country Healthcare, Inc.
Medical - Care Facilities
Market Cap$426M
5Y Perf.+117.1%
AMN
AMN Healthcare Services, Inc.
Medical - Care Facilities
Market Cap$1.12B
5Y Perf.-34.7%
SBFM
Sunshine Biopharma, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$737K
5Y Perf.-99.4%
TBI
TrueBlue, Inc.
Staffing & Employment Services
Market Cap$170M
5Y Perf.-63.7%
SXTC vs CCRN vs AMN vs SBFM vs TBI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SXTC | CCRN | AMN | SBFM | TBI |
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Care Facilities | Medical - Care Facilities | Drug Manufacturers - Specialty & Generic | Staffing & Employment Services |
| Market Cap | $671K | $426M | $1.12B | $737K | $170M |
| Revenue (TTM) | $2M | $761M | $3.42B | $36M | $1.25B |
| Net Income (TTM) | $-3M | $-99M | $-32M | $-6M | $-53M |
| Gross Margin | 21.1% | 18.2% | 27.6% | 33.3% | 28.4% |
| Operating Margin | -154.0% | -0.9% | 0.3% | -17.9% | -2.6% |
| Forward P/E | — | 156.2x | 14.2x | — | — |
| Total Debt | $984K | $2M | $803M | $952K | $171M |
| Cash & Equiv. | $18M | $109M | $34M | $10M | $25M |
SXTC vs CCRN vs AMN vs SBFM vs TBI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SXTC
CCRN
AMN
SBFM
TBI
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| China SXT Pharmaceu… (SXTC) | 100 | 0.0 | -100.0% |
| Cross Country Healt… (CCRN) | 100 | 217.1 | +117.1% |
| AMN Healthcare Serv… (AMN) | 100 | 65.3 | -34.7% |
| Sunshine Biopharma,… (SBFM) | 100 | 0.6 | -99.4% |
| TrueBlue, Inc. (TBI) | 100 | 36.3 | -63.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SXTC vs CCRN vs AMN vs SBFM vs TBI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AMN leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Cross Country Healthcare, Inc. is the stronger pick specifically for capital preservation and lower volatility. SBFM also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SXTC
China SXT Pharmaceuticals, Inc.
The Healthcare Pick
SXTC lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
CCRN
Cross Country Healthcare, Inc.
The Income Pick
CCRN is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 1 yrs, beta 0.68
- -9.9% 10Y total return vs AMN's -24.7%
- Lower volatility, beta 0.68, Low D/E 0.7%, current ratio 3.78x
- Beta 0.68, current ratio 3.78x
Best for: income & stability and long-term compounding
AMN
AMN Healthcare Services, Inc.
The Value Play
AMN carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- -0.9% margin vs SXTC's -189.8%
- +42.5% vs SXTC's -99.4%
- -1.4% ROA vs CCRN's -19.8%, ROIC 1.6% vs -0.9%
Best for: value and quality
SBFM
Sunshine Biopharma, Inc.
The Growth Play
SBFM ranks third and is worth considering specifically for growth exposure.
- Rev growth 44.7%, EPS growth 97.9%, 3Y rev CAGR 434.5%
- 44.7% revenue growth vs CCRN's -21.6%
Best for: growth exposure
TBI
TrueBlue, Inc.
The Industrials Pick
Among these 5 stocks, TBI doesn't own a clear edge in any measured category.
Best for: industrials exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SBFM | 44.7% revenue growth vs CCRN's -21.6% |
| Value | AMN | Better valuation composite |
| Quality / Margins | AMN | -0.9% margin vs SXTC's -189.8% |
| Stability / Safety | CCRN | Beta 0.68 vs SBFM's 1.33, lower leverage |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | AMN | +42.5% vs SXTC's -99.4% |
| Efficiency (ROA) | AMN | -1.4% ROA vs CCRN's -19.8%, ROIC 1.6% vs -0.9% |
SXTC vs CCRN vs AMN vs SBFM vs TBI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
Segment breakdown not available.
FY 2025
SXTC vs CCRN vs AMN vs SBFM vs TBI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAMNLAGGINGTBI
Who Leads Where
AMN leads in 3 of 6 categories
CCRN leads 2 • SXTC leads 0 • SBFM leads 0 • TBI leads 0 • 1 tied
Explore the data ↓TBITrueBlue, Inc.
0leads
SBFMSunshine Biopharma, I…
0leads
SXTCChina SXT Pharmaceuti…
0leads
CCRNCross Country Healthc…
2leads
AMNAMN Healthcare Servic…
3leads
6 Total Categories
CATEGORYLEADERvs CCRNvs SXTCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AMN5/6
Valuation MetricsMultiples, price ratios, and targets
AMN4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AMN5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CCRN4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
CCRN1/1
Income & Cash Flow (Last 12 Months)
AMN leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMN is the larger business by revenue, generating $3.4B annually — 1964.1x SXTC's $2M. AMN is the more profitable business, keeping -0.9% of every revenue dollar as net income compared to SXTC's -189.8%. On growth, AMN holds the edge at +99.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SXTCChina SXT Pharmac… | CCRNCross Country Hea… | AMNAMN Healthcare Se… | SBFMSunshine Biopharm… | TBITrueBlue, Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $761M | $3.4B | $36M | $1.2B |
| EBITDAEarnings before interest/tax | -$3M | $9M | $127M | -$6M | -$10M |
| Net IncomeAfter-tax profit | -$3M | -$99M | -$32M | -$6M | -$53M |
| Free Cash FlowCash after capex | -$2M | $40M | $706M | -$9M | -$60M |
| Gross MarginGross profit ÷ Revenue | +21.1% | +18.2% | +27.6% | +33.3% | +28.4% |
| Operating MarginEBIT ÷ Revenue | -154.0% | -0.9% | +0.3% | -17.9% | -2.6% |
| Net MarginNet income ÷ Revenue | -189.8% | -13.0% | -0.9% | -17.4% | -4.3% |
| FCF MarginFCF ÷ Revenue | -134.8% | +5.2% | +20.7% | -26.1% | -4.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.8% | -100.0% | +99.9% | +1.2% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -119.1% | -6.0% | +56.8% | +21.5% | -37.5% |
AMN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
AMN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMN's 10.0x EV/EBITDA is more attractive than TBI's 154.1x.
| Metric | SXTCChina SXT Pharmac… | CCRNCross Country Hea… | AMNAMN Healthcare Se… | SBFMSunshine Biopharm… | TBITrueBlue, Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $670,507 | $426M | $1.1B | $736,836 | $170M |
| Enterprise ValueMkt cap + debt − cash | -$16M | $320M | $1.9B | -$8M | $316M |
| Trailing P/EPrice ÷ TTM EPS | -0.20x | -4.50x | -11.68x | -0.14x | -3.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 156.16x | 14.24x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 23.97x | 9.95x | — | 154.12x |
| Price / SalesMarket cap ÷ Revenue | 0.39x | 0.40x | 0.41x | 0.02x | 0.11x |
| Price / BookPrice ÷ Book value/share | 0.04x | 1.32x | 1.74x | 0.03x | 0.61x |
| Price / FCFMarket cap ÷ FCF | — | 10.63x | 4.79x | — | — |
AMN leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
AMN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
AMN delivers a -5.0% return on equity — every $100 of shareholder capital generates $-5 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMN's 1.25x. On the Piotroski fundamental quality scale (0–9), CCRN scores 6/9 vs SBFM's 1/9, reflecting solid financial health.
| Metric | SXTCChina SXT Pharmac… | CCRNCross Country Hea… | AMNAMN Healthcare Se… | SBFMSunshine Biopharm… | TBITrueBlue, Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.4% | -27.1% | -5.0% | -24.6% | -18.7% |
| ROA (TTM)Return on assets | -15.2% | -19.8% | -1.4% | -19.7% | -8.1% |
| ROICReturn on invested capital | -142.0% | -0.9% | +1.6% | -42.9% | -5.2% |
| ROCEReturn on capital employed | -17.9% | -0.8% | +2.0% | -25.2% | -5.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 5 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.06x | 0.01x | 1.25x | 0.04x | 0.62x |
| Net DebtTotal debt minus cash | -$17M | -$106M | $769M | -$9M | $146M |
| Cash & Equiv.Liquid assets | $18M | $109M | $34M | $10M | $25M |
| Total DebtShort + long-term debt | $983,877 | $2M | $803M | $952,480 | $171M |
| Interest CoverageEBIT ÷ Interest expense | -4.14x | -1.39x | 1.23x | -757.53x | -46.19x |
AMN leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CCRN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CCRN five years ago would be worth $7,685 today (with dividends reinvested), compared to $1 for SBFM. Over the past 12 months, AMN leads with a +42.5% total return vs SXTC's -99.4%. The 3-year compound annual growth rate (CAGR) favors CCRN at -17.5% vs SBFM's -89.9% — a key indicator of consistent wealth creation.
| Metric | SXTCChina SXT Pharmac… | CCRNCross Country Hea… | AMNAMN Healthcare Se… | SBFMSunshine Biopharm… | TBITrueBlue, Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -99.4% | +63.5% | +91.6% | -18.0% | +27.5% |
| 1-Year ReturnPast 12 months | -99.4% | -5.2% | +42.5% | -14.6% | +31.4% |
| 3-Year ReturnCumulative with dividends | -99.8% | -43.9% | -67.9% | -99.9% | -62.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | -23.1% | -68.5% | -100.0% | -79.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | -9.9% | -24.7% | -100.0% | -70.5% |
| CAGR (3Y)Annualised 3-year return | -87.6% | -17.5% | -31.5% | -89.9% | -28.1% |
CCRN leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CCRN and AMN each lead in 1 of 2 comparable metrics.
Risk & Volatility
CCRN is the less volatile stock with a 0.68 beta — it tends to amplify market swings less than SBFM's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMN currently trades 100.0% from its 52-week high vs SXTC's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SXTCChina SXT Pharmac… | CCRNCross Country Hea… | AMNAMN Healthcare Se… | SBFMSunshine Biopharm… | TBITrueBlue, Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 0.68x | 1.12x | 1.33x | 0.98x |
| 52-Week HighHighest price in past year | $1046.98 | $14.99 | $28.98 | $2.43 | $7.78 |
| 52-Week LowLowest price in past year | $0.08 | $7.43 | $14.87 | $0.95 | $3.18 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +87.9% | +100.0% | +43.2% | +72.1% |
| RSI (14)Momentum oscillator 0–100 | 29.3 | 78.8 | 66.3 | 56.2 | 81.5 |
| Avg Volume (50D)Average daily shares traded | 53K | 578K | 899K | 37K | 387K |
Evenly matched — CCRN and AMN each lead in 1 of 2 comparable metrics.
Analyst Outlook
CCRN leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CCRN as "Hold", AMN as "Buy", TBI as "Buy". Consensus price targets imply -2.0% upside for TBI (target: $6) vs -19.5% for CCRN (target: $11).
| Metric | SXTCChina SXT Pharmac… | CCRNCross Country Hea… | AMNAMN Healthcare Se… | SBFMSunshine Biopharm… | TBITrueBlue, Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | — | Buy |
| Price TargetConsensus 12-month target | — | $10.61 | $23.38 | — | $5.50 |
| # AnalystsCovering analysts | — | 14 | 17 | — | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% | 0.0% | +100.0% | +0.6% |
CCRN leads this category, winning 1 of 1 comparable metric.
Key Takeaway
AMN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). CCRN leads in 2 (Total Returns, Analyst Outlook). 1 tied.
Best OverallAMN Healthcare Services, In… (AMN)Leads 3 of 6 categories
Loading custom metrics...
SXTC vs CCRN vs AMN vs SBFM vs TBI: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SXTC or CCRN or AMN or SBFM or TBI a better buy right now?
For growth investors, Sunshine Biopharma, Inc.
(SBFM) is the stronger pick with 44. 7% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Analysts rate AMN Healthcare Services, Inc. (AMN) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SXTC or CCRN or AMN or SBFM or TBI?
Over the past 5 years, Cross Country Healthcare, Inc.
(CCRN) delivered a total return of -23. 1%, compared to -100. 0% for Sunshine Biopharma, Inc. (SBFM). Over 10 years, the gap is even starker: CCRN returned -9. 9% versus SBFM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SXTC or CCRN or AMN or SBFM or TBI?
By beta (market sensitivity over 5 years), Cross Country Healthcare, Inc.
(CCRN) is the lower-risk stock at 0. 68β versus Sunshine Biopharma, Inc. 's 1. 33β — meaning SBFM is approximately 96% more volatile than CCRN relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 125% for AMN Healthcare Services, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — SXTC or CCRN or AMN or SBFM or TBI?
By revenue growth (latest reported year), Sunshine Biopharma, Inc.
(SBFM) is pulling ahead at 44. 7% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: Sunshine Biopharma, Inc. grew EPS 97. 9% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, SBFM leads at 434. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SXTC or CCRN or AMN or SBFM or TBI?
TrueBlue, Inc.
(TBI) is the more profitable company, earning -3. 0% net margin versus -189. 8% for China SXT Pharmaceuticals, Inc. — meaning it keeps -3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMN leads at 1. 2% versus -154. 0% for SXTC. At the gross margin level — before operating expenses — SBFM leads at 30. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SXTC or CCRN or AMN or SBFM or TBI more undervalued right now?
On forward earnings alone, AMN Healthcare Services, Inc.
(AMN) trades at 14. 2x forward P/E versus 156. 2x for Cross Country Healthcare, Inc. — 141. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TBI: -2. 0% to $5. 50.
07Which pays a better dividend — SXTC or CCRN or AMN or SBFM or TBI?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SXTC or CCRN or AMN or SBFM or TBI better for a retirement portfolio?
For long-horizon retirement investors, Cross Country Healthcare, Inc.
(CCRN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 68)). Both have compounded well over 10 years (CCRN: -9. 9%, SBFM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SXTC and CCRN and AMN and SBFM and TBI?
These companies operate in different sectors (SXTC (Healthcare) and CCRN (Healthcare) and AMN (Healthcare) and SBFM (Healthcare) and TBI (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SXTC is a small-cap quality compounder stock; CCRN is a small-cap quality compounder stock; AMN is a small-cap quality compounder stock; SBFM is a small-cap high-growth stock; TBI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(SXTC: -7.8% · CCRN: -100.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.